Lymphoma won't stop Iommi and Sabbath from playing Donington
While there is still no official word about whether Black Sabbath will be able to carry out the band's world tour on account of guitarist Tony Iommi's diagnosis with an unnamed subtype of lymphoma earlier this month, they appear to be keeping at least one upcoming concert date.
According to the organizer of one of the largest annual UK concerts, the Download Festival, Black Sabbath will be headlining as per the original billing.
"As far as I'm aware, everything is fine," said Andy Copping. "I've been told that Black Sabbath are going to be playing Download. I don't want people to worry unduly about that, we should all just send our thoughts and best wishes to Tony Iommi."
The Download Festival takes place in mid-June at Donington Park. Headliners include Black Sabbath, The Prodigy and Metallica.
Source: RTT News
Photo by Adam Bielawski
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
